Bausch, Teva accused in US court of illegally delaying generic Xifaxan
MLex Summary: Bausch Health and Teva Pharmaceuticals entered into an illegal pay-for-delay agreement to keep a generic competitor to Bausch’s irritable-bowel-syndrome treatment Xifaxan off the market, according to a US complaint. “Teva’s...To view the full article, register now.
Already a subscriber? Click here to view full article